Condition or Therapy:

Low-grade gliomas and other Ras/Raf/MAP pathway activated tumors

Category:

Cancer and Blood Disorders

Study Number: SC-9012

What is the goal of this study?

The main purpose of this study is to determine the best dose of the experimental drug, MEK162 and to find out whether the drug is safe in children and adolescents with tumors that have grown or come back despite standard therapy.

Another purpose of this study is to measure the concentration of drug in the blood to help understand how much drug gets into the body and how quickly the drug is removed from the body.

Additionally, this study aims to determine whether MEK162 turns off the Ras/Raf/MAP pathway as expected by measuring this pathway in blood cells.

Researchers also hope to start finding out whether or not MEK162 causes different types of tumors in children to shrink or stop growing.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are between ages 1 to 18
  • Have recurrent or progressive disease
  • Tumor imaging from at least two-time points must be available to document radiographic

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read more about this study at clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.


Study Location(s):

Seattle Children's Hospital main campus

Principal Investigator:

Dr. Sarah Leary